Emerging trends in pharmaceutical design and drug manufacturing are shifting toward presenting the market with new ways to develop medications. Specialty medications continue to be a major area of pharmaceutical development and have become widely discussed in workers’ comp due to their significant costs. Although they represent approximately 1% of drug utilization, they account for nearly 7% of prescription drug costs and represent the fastest-growing segment of the U.S. pharmaceutical market. While specialty drug products are often associated with a hefty price tag, some can offer clinical advantages when deployed for the right patient at the right time, making careful oversight and patient selection imperative to achieving desired outcomes in this space. Watch the video blog to learn more.
More stories
Ask The Pharmacist: Why Migraine Medications in Work Comp Deserve a Closer Review
Migraine headaches can be disabling, difficult to document and costly to treat. In workers’ compensation, they also create claim complexity when causation, medication choice or treatment progress is not clearly supported.
In-Network and Out-of-Network Trends
This analysis provides a comprehensive examination of prescription utilization across both in-network and out-of-network channels including retail pharmacies, mail-order services, and paper-based medical bill submissions. This dual-lens approach captures the full prescription landscape that extends beyond traditional pharmacy benefit management reporting, revealing critical cost and utilization patterns across all jurisdictions. While in-network channels demonstrate the real-time effectiveness of integrated clinical controls and cost management strategies, out-of-network data, often representing acute treatment episodes captured through medical bill review, exposes significant cost management opportunities and pricing anomalies. Together, these perspectives illuminate where pharmacy dollars are spent, how prescriptions are managed, and where targeted interventions can drive the greatest impact on both clinical outcomes and costs.
Beyond the Return Date
A return-to-work plan can be medically sound and still fall short. The employee may be released to return, restrictions may be documented and accommodations may be approved. But a return sustainable? The goal is to help employees return in a way that is sustainable.
What Causes Bodily Injury Claim Overpayments and How to Prevent Them
Learn why bodily injury claims are overpaid and how consistent demand evaluation improves negotiation outcomes and reduces claim leakage
Life After Amputation: Coordinating Advanced Recovery Options
Catastrophic case management supports amputation recovery by coordinating prosthetic planning, rehabilitation and practical resources for injured employees.
The Largest Nuclear Verdicts in Q2 2026: Social Inflation Continues to Hinder Casualty Lines
A new Financial Times feature explores the forces driving nuclear verdicts and how the industry is responding, with insights from Enlyte's Michele Hibbert.